Immunotherapy and Melanoma Research Get Big Boost with Bloomberg-Kimmel Institute

WASHINGTON–(BUSINESS WIRE)–The promising field of immunotherapy, in which melanoma research has
played a significant role, got a massive boost yesterday with the
announcement of the formation of the Bloomberg-Kimmel Institute for
Cancer Immunotherapy at Johns Hopkins University. Led by Drew Pardoll
and including prominent melanoma researchers such as Suzanne Topalian, a
board member of the Melanoma Research Alliance (MRA), the new institute
will provide much-needed resources to harness the power of the immune
system to fight cancer.

“We applaud the creation of the new institute and welcome the focus this
brings to the power of immunotherapy in fighting melanoma and other
cancers,” said Debra Black, co-founder and chair of MRA, the largest
private funder of melanoma research in the world. “MRA has long
supported the immunotherapy research of Drew and Suzanne and are hopeful
that they and other researchers will continue to provide insights into
the causes of and treatments for cancers that affect millions of people.”

MRA has supported immunotherapy research since its formation in 2007,
including team science awards to Pardoll and Topalian at Johns Hopkins.
Topalian served as MRA’s first chief science officer and, in addition to
her board seat, currently serves on the Medical Advisory Panel and as
chair of its Scientific Advisory Panel. Both Pardoll and Topalian serve
on MRA’s Grant Review Committee, which provides scientific, merit-based
peer review of research proposals submitted to MRA.

About The Melanoma Research Alliance

MRA is a public charity formed in 2007 under the auspices of the Milken
Institute, with the generous founding support of Debra and Leon Black.
MRA is the largest private funder of melanoma research and has provided
nearly $68 million to research seeking to better prevent, diagnose and
treat melanoma, the deadliest type of skin cancer. Due to the ongoing
support of its founders, 100 percent of every dollar MRA raises goes to
support its melanoma research program. MRA’s ability to fund
wide-ranging research in melanoma is amplified by unique collaborations
and partnerships with individuals, private foundations and corporations.
for more information, or follow us on Twitter
or Facebook.


Anreder & Company
Steven S. Anreder –
Wichman –